In response to provider concerns about administrative burden, CVS Caremark has indicated it will revise its prior authorization forms in January 2022.
In July, CVS Caremark changed its prior authorization forms for many biologic drugs, creating an increased administrative burden for rheumatology practices. Chief among the many complaints the ACR received were new criteria around the evaluation of treatment efficacy for continuation of therapy requests. ACR leaders shared these concerns with CVS Caremark and received reassurance that revised forms will be implemented in January 2022.
The ACR will continue to monitor this issue to ensure it is appropriately resolved. We encourage members to contact [email protected] with any questions or concerns.
